Cytokine, Sickness Behavior, and Depression

Immunology and Allergy Clinics of North America

Volumn 29, Issue 2, 2009, Pages 247-264

  Dantzer, Robert ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Behavior; Brain; Cytokine; Depression; Inflammation; Interleukin 1; Sickness; Tumor necrosis factor

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; BRAIN RECEPTOR; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; NEUROTRANSMITTER; PAROXETINE; PROSTAGLANDIN E2; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

BEHAVIOR; BRAIN REGION; CYTOKINE PRODUCTION; DEPRESSION; DIET RESTRICTION; FEVER; HUMAN; HUMORAL IMMUNITY; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; ILLNESS BEHAVIOR; INFLAMMATION; INNATE IMMUNITY; MOOD; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN LOCALIZATION; REVIEW; TISSUE DISTRIBUTION;

EID: 64649092338     PISSN: 08898561     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.iac.2009.02.002     Document Type: Review

References (90)

1. Dantzer R., O'Connor J.C., Freund G.G., et al. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9 (2008) 46-56
2. Konsman J.P., Parnet P., and Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 25 (2002) 154-159
3. Barton G.M., and Medzhitov R. Toll-like receptor signaling pathways. Science 300 (2003) 1524-1525
4. Romanovsky A., Almeida M.C., Aronoff D.M., et al. Fever and hypothermia in systemic inflammation: recent discoveries and revisions. Front Biosci 10 (2005) 2193-2216
5. Berkenbosch F., van Oers J., del Rey A., et al. Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1. Science 238 (1987) 524-526
6. Ericsson A., Kovacs K.J., and Sawchenko P.E. A functional anatomical analysis of central pathways subserving the effects of interleukin-1 on stress-related neuroendocrine neurons. J Neurosci 14 (1994) 897-913
7. Goehler L.E., Gaykema R.P., Nguyen K.T., et al. Interleukin-1beta in immune cells of the abdominal vagus nerve: a link between the immune and nervous systems?. J Neurosci 19 (1999) 2799-2806
8. Ek M., Kurosawa M., Lundeberg T., et al. Activation of vagal afferents after intravenous injection of interleukin-1beta: role of endogenous prostaglandins. J Neurosci 18 (1998) 9471-9479
9. Wan W., Wetmore L., Sorensen C.M., et al. Neural and biochemical mediators of endotoxin and stress-induced c-fos expression in the rat brain. Brain Res Bull 34 (1994) 7-14
10. Bluthe R.M., Walter V., Parnet P., et al. Lipopolysaccharide induces sickness behaviour in rats by a vagal mediated mechanism. C R Acad Sci III 317 (1994) 499-503
11. Bluthe R.M., Michaud B., Kelley K.W., et al. Vagotomy attenuates behavioural effects of interleukin-1 injected peripherally but not centrally. Neuroreport 7 (1996) 1485-1488
12. Bluthe R.M., Michaud B., Kelley K.W., et al. Vagotomy blocks behavioural effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes. Neuroreport 7 (1996) 2823-2827
13. Marvel F.A., Chen C.C., Badr N., et al. Reversible inactivation of the dorsal vagal complex blocks lipopolysaccharide-induced social withdrawal and c-Fos expression in central autonomic nuclei. Brain Behav Immun 18 (2004) 123-134
14. Romeo H.E., Tio D.L., and Taylor A.N. Effects of glossopharyngeal nerve transection on central and peripheral cytokines and serum corticosterone induced by localized inflammation. J Neuroimmunol 136 (2003) 104-111
15. Romeo H.E., Tio D.L., Rahman S.U., et al. The glossopharyngeal nerve as a novel pathway in immune-to-brain communication: relevance to neuroimmune surveillance of the oral cavity. J Neuroimmunol 115 (2001) 91-100
16. Konsman J.P., Luheshi G.N., Bluthe R.M., et al. The vagus nerve mediates behavioural depression, but not fever, in response to peripheral immune signals; a functional anatomical analysis. Eur J Neurosci 12 (2000) 4434-4446
17. Rivest S., Lacroix S., Vallieres L., et al. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 223 (2000) 22-38
18. Romanovsky A.A. Thermoregulatory manifestations of systemic inflammation: lessons from vagotomy. Auton Neurosci 85 (2000) 39-48
19. Laye S., Gheusi G., Cremona S., et al. Endogenous brain IL-1 mediates LPS-induced anorexia and hypothalamic cytokine expression. Am J Physiol Regul Integr Comp Physiol 279 (2000) R93-R98
20. Kent S., Bluthe R.M., Dantzer R., et al. Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc Natl Acad Sci USA 89 (1992) 9117-9120
21. van Dam A.M., Brouns M., Louisse S., et al. Appearance of interleukin-1 in macrophages and in ramified microglia in the brain of endotoxin-treated rats: a pathway for the induction of non-specific symptoms of sickness?. Brain Res 588 (1992) 291-296
22. Konsman J.P., Kelley K., and Dantzer R. Temporal and spatial relationships between lipopolysaccharide-induced expression of Fos, interleukin-1beta and inducible nitric oxide synthase in rat brain. Neuroscience 89 (1999) 535-548
23. Ericsson A., Liu C., Hart R.P., et al. Type 1 interleukin-1 receptor in the rat brain: distribution, regulation, and relationship to sites of IL-1-induced cellular activation. J Comp Neurol 361 (1995) 681-698
24. Vitkovic L., Konsman J.P., Bockaert J., et al. Cytokine signals propagate through the brain. Mol Psychiatry 5 (2000) 604-615
25. Reyes T.M., and Sawchenko P.E. Involvement of the arcuate nucleus of the hypothalamus in interleukin-1-induced anorexia. J Neurosci 22 (2002) 5091-5099
26. Laye S., Bluthe R.M., Kent S., et al. Subdiaphragmatic vagotomy blocks induction of IL-1 beta mRNA in mice brain in response to peripheral LPS. Am J Physiol 268 5 Pt 2 (1995) R1327-R1331
27. Hansen M.K., Nguyen K.T., Goehler L.E., et al. Effects of vagotomy on lipopolysaccharide-induced brain interleukin-1beta protein in rats. Auton Neurosci 85 (2000) 119-126
28. Hosoi T., Okuma Y., and Nomura Y. Electrical stimulation of afferent vagus nerve induces IL-1beta expression in the brain and activates HPA axis. Am J Physiol Regul Integr Comp Physiol 279 (2000) R141-R147
29. Dantzer R., Konsman J.P., Bluthe R.M., et al. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent?. Auton Neurosci 85 (2000) 60-65
30. Dunn A.J., Wang J., and Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 461 (1999) 117-127
31. Anforth H.R., Bluthe R.M., Bristow A., et al. Biological activity and brain actions of recombinant rat interleukin-1alpha and interleukin-1beta. Eur Cytokine Netw 9 (1998) 279-288
32. Lenczowski M.J., Bluthe R.M., Roth J., et al. Central administration of rat IL-6 induces HPA activation and fever but not sickness behavior in rats. Am J Physiol 276 3 Pt 2 (1999) R652-R658
33. Bluthe R.M., Michaud B., Poli V., et al. Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice. Physiol Behav 70 (2000) 367-373
34. Bluthe R.M., Laye S., Michaud B., et al. Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: a study with interleukin-1 type I receptor-deficient mice. Eur J Neurosci 12 (2000) 4447-4456
35. Konsman J.P., Tridon V., and Dantzer R. Diffusion and action of intracerebroventricularly injected interleukin-1 in the CNS. Neuroscience 101 (2000) 957-967
36. Burgess W., Gheusi G., Yao J., et al. Interleukin-1beta-converting enzyme-deficient mice resist central but not systemic endotoxin-induced anorexia. Am J Physiol 274 6 Pt 2 (1998) R1829-R1833
37. Li X., and Qin J. Modulation of Toll-interleukin 1 receptor mediated signaling. J Mol Med 83 (2005) 258-266
38. Cullinan E.B., Kwee L., Nunes P., et al. IL-1 receptor accessory protein is an essential component of the IL-1 receptor. J Immunol 161 (1998) 5614-5620
39. French R.A., VanHoy R.W., Chizzonite R., et al. Expression and localization of p80 and p68 interleukin-1 receptor proteins in the brain of adult mice. J Neuroimmunol 93 (1999) 194-202
40. Katsuura G., Gottschall P.E., and Arimura A. Identification of a high-affinity receptor for interleukin-1 beta in rat brain. Biochem Biophys Res Commun 156 (1988) 61-67
41. Nishiyori A., Minami M., Takami S., et al. Type 2 interleukin-1 receptor mRNA is induced by kainic acid in the rat brain. Brain Res Mol Brain Res 50 (1997) 237-245
42. Docagne F., Campbell S.J., Bristow A.F., et al. Differential regulation of type I and type II interleukin-1 receptors in focal brain inflammation. Eur J Neurosci 21 (2005) 1205-1214
43. Ilyin S.E., and Plata-Salaman C.R. In vivo regulation of the IL-1 beta system (ligand, receptors I and II, receptor accessory protein, and receptor antagonist) and TNF-alpha mRNAs in specific brain regions. Biochem Biophys Res Commun 227 (1996) 861-867
44. Takao T., Tracey D.E., Mitchell W.M., et al. Interleukin-1 receptors in mouse brain: characterization and neuronal localization. Endocrinology 127 (1990) 3070-3078
45. Ban E., Milon G., Prudhomme N., et al. Receptors for interleukin-1 (alpha and beta) in mouse brain: mapping and neuronal localization in hippocampus. Neuroscience 43 (1991) 21-30
46. Parnet P., Amindari S., Wu C., et al. Expression of type I and type II interleukin-1 receptors in mouse brain. Brain Res Mol Brain Res 27 (1994) 63-70
47. Konsman J.P., Vigues S., Mackerlova L., et al. Rat brain vascular distribution of interleukin-1 type-1 receptor immunoreactivity: relationship to patterns of inducible cyclooxygenase expression by peripheral inflammatory stimuli. J Comp Neurol 472 (2004) 113-129
48. Nadjar A., Combe C., Laye S., et al. Nuclear factor kappaB nuclear translocation as a crucial marker of brain response to interleukin-1. A study in rat and interleukin-1 type I deficient mouse. J Neurochem 87 (2003) 1024-1036
49. Gabellec M.M., Jafarian-Tehrani M., Griffais R., et al. Interleukin-1 receptor accessory protein transcripts in the brain and spleen: kinetics after peripheral administration of bacterial lipopolysaccharide in mice. Neuroimmunomodulation 3 (1996) 304-309
50. Liu C., Chalmers D., Maki R., et al. Rat homolog of mouse interleukin-1 receptor accessory protein: cloning, localization and modulation studies. J Neuroimmunol 66 (1996) 41-48
51. Cremona S., Goujon E., Kelley K.W., et al. Brain type I but not type II IL-1 receptors mediate the effects of IL-1 beta on behavior in mice. Am J Physiol 274 3 Pt 2 (1998) R735-R740
52. Sonti G., Flynn M.C., and Plata-Salaman C.R. Interleukin-1 (IL-1) receptor type I mediates anorexia but not adipsia induced by centrally administered IL-1beta. Physiol Behav 62 (1997) 1179-1183
53. Liege S., Laye S., Li K.S., et al. Interleukin 1 receptor accessory protein (IL-1RAcP) is necessary for centrally mediated neuroendocrine and immune responses to IL-1beta. J Neuroimmunol 110 (2000) 134-139
54. Quan N., Whiteside M., Kim L., et al. Induction of inhibitory factor kappaBalpha mRNA in the central nervous system after peripheral lipopolysaccharide administration: an in situ hybridization histochemistry study in the rat. Proc Natl Acad Sci USA 94 (1997) 10985-10990
55. Kubota T., Kushikata T., Fang J., et al. Nuclear factor-kappaB inhibitor peptide inhibits spontaneous and interleukin-1beta-induced sleep. Am J Physiol Regul Integr Comp Physiol 279 (2000) R404-R413
56. Nadjar A., Bluthe R.M., May M.J., et al. Inactivation of the cerebral NFkappaB pathway inhibits interleukin-1beta-induced sickness behavior and c-Fos expression in various brain nuclei. Neuropsychopharmacology 30 (2005) 1492-1499
57. Kelly A., Vereker E., Nolan Y., et al. Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus. J Biol Chem 278 (2003) 19453-19462
58. Godbout J.P., Chen J., Abraham J., et al. Exaggerated neuroinflammation and sickness behavior in aged mice following activation of the peripheral innate immune system. FASEB J 19 (2005) 1329-1331
59. O'Connor J.C., Satpathy A., Hartman M.E., et al. IL-1beta-mediated innate immunity is amplified in the db/db mouse model of type 2 diabetes. J Immunol 174 (2005) 4991-4997
60. Perry V.H. The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease. Brain Behav Immun 18 (2004) 407-413
61. Hart B.L. Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 12 (1988) 123-137
62. Aubert A., Goodall G., Dantzer R., et al. Differential effects of lipopolysaccharide on pup retrieving and nest building in lactating mice. Brain Behav Immun 11 (1997) 107-118
63. Lutgendorf S.K., Garand L., Buckwalter K.C., et al. Life stress, mood disturbance, and elevated interleukin-6 in healthy older women. J Gerontol A Biol Sci Med Sci 54 (1999) M434-M439
64. Kiecolt-Glaser J.K., and Glaser R. Depression and immune function: central pathways to morbidity and mortality. J Psychosom Res 53 (2002) 873-876
65. Alesci S., Martinez P.E., Kelkar S., et al. Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab 90 (2005) 2522-2530
66. Maes M., Bosmans E., and Meltzer H.Y. Immunoendocrine aspects of major depression. Relationships between plasma interleukin-6 and soluble interleukin-2 receptor, prolactin and cortisol. Eur Arch Psychiatry Clin Neurosci 245 (1995) 172-178
67. Maes M., Bosmans E., De Jongh R., et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokines 9 (1997) 853-858
68. Brambilla F., and Maggioni M. Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand 97 (1998) 309-313
69. Capuron L., Ravaud A., Miller A.H., et al. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav Immun 18 (2004) 205-213
70. Capuron L., Gumnick J.F., Musselman D.L., et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26 (2002) 643-652
71. Bull S.J., Huezo-Diaz P., Binder E.B., et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry (2008, May 6) [Epub ahead of print]
72. Kraus M.R., Al-Taie O., Schäfer A., et al. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 132 (2007) 1279-1286
73. Capuron L., and Ravaud A. Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med 340 (1999) 1370
74. Miyaoka H., Otsubo T., Kamijima K., et al. Depression from interferon therapy in patients with hepatitis C. Am J Psychiatry 156 (1999) 1120
75. Capuron L., Neurauter G., Musselman D.L., et al. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 54 (2003) 906-914
76. Constant A., Castera L., Dantzer R., et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry 66 (2005) 1050-1057
77. Capuron L., Ravaud A., Neveu P.J., et al. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry 7 (2002) 468-473
78. Maes M., Bonaccorso S., Marino V., et al. Treatment with interferon-alpha (IFN alpha) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN alpha-induced depressive and anxiety symptoms and immune activation. Mol Psychiatry 6 (2001) 475-480
79. Lestage J., Verrier D., Palin K., et al. The enzyme indoleamine 2,3-dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav Immun 16 (2002) 596-601
80. Frenois F., Moreau M., O'Connor J., et al. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology 32 (2007) 516-531
81. Moreau M., Andre C., O'Connor J.C., et al. Inoculation of Bacillus Calmette-Guerin to mice induces an acute episode of sickness behavior followed by chronic depressive-like behavior. Brain Behav Immun 22 (2008) 1087-1095
82. Andre C., O'Connor J.C., Kelley K.W., et al. Spatio-temporal differences in the profile of murine brain expression of proinflammatory cytokines and indoleamine 2,3 dioxygenase in response to peripheral lipopolysaccharide administration. J Neuroimmunol 200 (2008) 90-99
83. O'Connor J.C., Lawson M.A., Andre C., et al. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3 dioxygenase activation in muce. Mol Psychiatry (2008;Jan 15) [Epub ahead of print]
84. Tyring S., Gottlieb A., Papp K., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet 367 (2006) 29-35
85. Schwarcz R., and Pellicciari R. Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther 303 (2002) 1-10
86. Wichers M.C., Koek G.H., Robaeys G., et al. IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry 10 (2005) 538-544
87. Juengling F.D., Ebert D., Gut O., et al. Prefrontal cortical hypometabolism during low-dose interferon alpha treatment. Psychopharmacology (Berl) 152 (2000) 383-389
88. Capuron L., Pagnoni G., Fornwalt F.B., et al. Brain metabolic changes and neurovegetative symptoms in medically ill patients undergoing interferon-alpha therapy. Abstr Soc Neurosci 660 (2005) 23
89. Appels A., Bar F.W., Bar J., et al. Inflammation, depressive symptomatology, and coronary artery disease. Psychosom Med 62 (2000) 601-605
90. Lesperance F., Frasure-Smith N., Theroux P., et al. The association between major depression and levels of soluble intercellular adhesion molecule 1, interleukin-6, and C-reactive protein in patients with recent acute coronary syndromes. Am J Psychiatry 161 (2004) 271-277